Anti-EphA2 FluorAbody
Cancer Research (e.g., Triple Negative Breast Cancer)
ResearchActive
Key Facts
Indication
Cancer Research (e.g., Triple Negative Breast Cancer)
Phase
Research
Status
Active
Company
About Sandia Biotech
Sandia Biotech is a private, early-stage biotech firm commercializing a novel fluorescent reagent platform called FluorAbodies. These reagents are single-chain variable fragments (ScFvs) genetically fused to fluorescent proteins, designed to overcome limitations of conventional antibody conjugates in research and diagnostics. The company appears to be in an early commercial phase, generating revenue through direct sales of its catalog products, with a primary focus on oncology biomarkers like HER2 and EphA2. Leadership includes co-founder and President Tony Pino, though the full team is not detailed on the public website.
View full company profile